Pharmacokinetics of methyldopa in man

J Pharmacol Exp Ther. 1976 Aug;198(2):264-77.

Abstract

Single doses of methyldopa were administered orally and intravenously as aqueous solutions to 12 healthy volunteers in a crossover study. Serial plasma and urine samples were analyzed specifically for methyldopa and its O-sulfate conjugate. Kinetic analyses of the results indicated that methyldopa disposition could be adequately represented by a two-compartment open model. Renal excretion accounted for about two-thirds of the plasma clearance of methylodopa. Absorption profiles were constructed with the aid of the pharmacokinetic model and contrasted with estimates of absorption which were model-independent. The mean fraction reaching the systemic circulation as methyldopa was estimated to be 0.25 (range 0.08-0.62 for n = 11). Although most of the absorption occurred within the first 5 hours oral administration, a minor component, suggestive of limited enterohepatic circulation, persisted from 9 to 36 hours. O-sulfate conjugation was route-dependent and appeared to be derived predominantly, if not exclusively, as a first-pass effect of absorption and/or enterophepatic circulation.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Biopharmaceutics
  • Clinical Trials as Topic
  • Enterohepatic Circulation
  • Half-Life
  • Humans
  • Injections, Intravenous
  • Intestinal Absorption
  • Kinetics
  • Male
  • Methyldopa / administration & dosage
  • Methyldopa / metabolism*
  • Models, Biological
  • Time Factors

Substances

  • Methyldopa